Federal Register / Vol. 73, No.
8 / Friday, January 11, 2008 / Notices 2055
referral or services for individuals or
couples where violence is occurring.
Applicants should be able to
demonstrate knowledge of the
information and services provided by
domestic violence coalitions within the
community.
vii. Funding Thresholds. The funding
thresholds for this program will be
revised to reflect ANA’s availability of
funds within this special initiative
program area. These thresholds allow
ANA to provide funding to the
maximum number of applicants. (Legal
authority: Section 803(a) and (d) and
803C of the Native American Programs
Act of 1974, as amended, 42 U.S.C. 2991
band 2991b–3.)
viii. Project Periods. The project
periods reflect the review and
assessment of projects monitored under
this special initiative program area.
These project periods allow ANA to
provide funding to the maximum
number of applicants. (Legal authority:
Section 803(a) and (d) and 803C of the
Native American Programs Act of 1974,
as amended, 42 U.S.C. 2991b and
2991b–3.)
In the FY 08 PA, project periods will
be:
• Priority Area 1—Planning: 12
months.
• Priority Area 2—Implementation:
36 months.
(C) ANA SEDS: In the FY 2008 PA for
both priority areas, the program areas of
interest (PAI) for social development
projects changed. The Administration
for Children and Families has expanded
the focus of healthy marriage to include
responsible fatherhood activities. In
order to eliminate redundancy, this
activity was added to the NAHMI PA.
The grandparents PAI was included to
promote inter-generational programs.
(Legal authority: Section 803(a) and (d)
and 803C of the Native American
Programs Act of 1974, as amended, 42
U.S.C. 2991b and 2991b–3.)
The FY 2008 PA will replace the
fatherhood PAI with the following:
• Projects that address the needs of
grandparents raising grandchildren.
(D) ANA Mitigation: The FY 2008 PA
removes all definitions related to in-
kind contributions, including in-kind
contributions, leveraged resources,
partnerships, and letters of
commitment. Furthermore, the required
number of impact indicators is reduced
to one. These changes are reflective of
Public Law 103–335 which does not
require matching funds. (Legal
ebenthall on PRODPC61 with NOTICES
authority: Section 803(a) and (d) and
803C of the Native American Programs
Act of 1974, as amended, 42 U.S.C.
2991b and 2991b–3 and Public Law
103–335.)
VerDate Aug<31>2005 14:33 Jan 10, 2008 Jkt 214001
Dated: January 2, 2008.
Quanah Crossland Stamps,
Commissioner, Administration for Native
Americans.
[FR Doc. 08–56 Filed 1–10–08 8:45 am]
BILLING CODE 4184–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007F–0478]
Kemira Oyi; Filing of Food Additive
Petition (Animal Use); Partially
Ammoniated Formic Acid
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that Kemira Oyi has filed a petition
proposing that the food additive
regulations be amended to provide for
the safe use of partially ammoniated
formic acid as a pH control agent in
swine feed.
DATES: Submit written or electronic
comments on the petitioner’s
environmental assessment by March 11,
2008.
ADDRESSES: You may submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to: http://
www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT:
Isabel W. Pocurull, Center for Veterinary
Medicine, Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240 453–6853,
email: isabel.pocurull@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
Federal Food, Drug, and Cosmetic Act
(section 409(b)(5) (21 U.S.C. 348(b)(5))),
notice is given that a food additive
petition (FAP 2258) has been filed by
Kristi O. Smedley, Center for Regulatory
Services, Inc., 5200 Wolf Run Shoals
Rd., Woodbridge, VA 22192–5755,
United States agent for Kemira Oyi,
Porkkalantatu 3, PO Box 330, 001000
Helsinki, Finland. The petition proposes
to amend the food additive regulations
in part 573—Food Additives Permitted
in Feed and Drinking Water of Animals
(21 CFR part 573) to provide for the safe
use of partially ammoniated formic acid
as a pH control agent in swine feed
when used at levels up to 1.2 percent of
the feed.
The potential environmental impact
of this action is being reviewed. To
PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\11JAN1.SGM
encourage public participation
consistent with regulations issued under
the National Environmental Policy Act
(40 CFR 1501.4(b)), the agency is
placing the environmental assessment
submitted with the petition that is the
subject of this notice on public display
at the Division of Dockets Management
(see ADDRESSES) for public review and
comment.
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
FDA will also place on public display
any amendments to, or comments on,
the petitioner’s environmental
assessment without further
announcement in the Federal Register.
If, based on its review, the agency finds
that an environmental impact statement
is not required and this petition results
in a regulation, the notice of availability
of the agency’s finding of no significant
impact and the evidence supporting that
finding will be published with the
regulation in the Federal Register in
accordance with 21 CFR 25.51(b).
Dated: December 31, 2007.
Bernadette Dunham,
Deputy Director, Center for Veterinary
Medicine.
[FR Doc. E8–316 Filed 1–10–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Anti-Infective Drugs Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Anti-Infective
Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
11JAN1
 2056 Federal Register / Vol. 73, No. 8 / Friday, January 11, 2008 / Notices
Date and Time: The meeting will be
held on February 27 and 28, 2008, from
8 a.m. to 5 p.m.
Location: Crowne Plaza Silver Spring,
The Ballrooms, 8777 Georgia Ave.,
Silver Spring, MD, 301–589–0800.
Contact Person: Sohail Mosaddegh,
Center for Drug Evaluation and Research
(HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
sohail.mosaddegh@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512530. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On February 27, 2008, the
committee will discuss new drug
application (NDA) 022–110, telavancin
powder for reconstitution and
intravenous administration, Theravance,
Inc., proposed for the treatment of
complicated skin and skin structure
infection. On February 28, 2008, the
committee will discuss NDA 022–132,
ceftobiprole medocaril (500 milligrams),
lyophilized powder for reconstitution
and intravenous administration,
Johnson and Johnson Pharmaceutical
Research and Development, LLC,
proposed for the treatment of
complicated skin and skin structure
infection.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at http://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2008 and scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
ebenthall on PRODPC61 with NOTICES
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before February 12, 2008.
Oral presentations from the public will
VerDate Aug<31>2005 14:33 Jan 10, 2008 Jkt 214001
be scheduled between approximately 11
a.m. and 12 noon. Those desiring to
make formal oral presentations should
notify the contact person and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before February 4, 2008. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
February 5, 2008.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Sohail
Mosaddegh at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
http://www.fda.gov/oc/advisory/
default.htm for procedures on public
conduct during advisory committee
meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: January 7, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8–343 Filed 1–10–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
PO 00000 Frm 00057 Fmt 4703 Sfmt 4703
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Initial Review Group, Subcommittee
J—Population and Patient-Oriented Training.
Date: February 13, 2008.
Time: 7:45 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westin Arlington Gateway, 801
North Glebe Road, Arlington, VA 22203.
Contact Person: Ilda M. McKenna, PhD,
Scientific Review Administrator, Research
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Boulevard, Room
8111, Bethesda, MD 20892, 301–496–7481,
mckennai@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: January 4, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–64 Filed 1–10–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\11JAN1.SGM 11JAN1